Notably, according to the 2018 NIA-AA research framework, the presence of Aβ deposits is a requirement for Alzheimer’s pathological change diagnosis and should be considered in early screening efforts and recruitment of individuals for clinical trials (Jack et al., 2018). The ability to detect and quantify Aβ deposits and related pathologies via noninvasive retinal imaging along with sensitive, routine, minimally invasive plasma AD biomarkers show great promise for diagnostic screening, monitoring of progression, and assessment of therapeutic efficacy (Hampel et al., 2018; Baldacci et al., 2020). The work described here combined with future advances may lead to clinical translation, discrimination of pathophysiological phenotypes during the AD continuum, and eventually a highly anticipated cure for this destructive disease.